Osimertinib Versus First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Metastatic EGFR-Mutant Non–Small Cell Lung Cancer: A Target Trial Emulation Study of Real-World Survival and Safety Outcomes
PURPOSE Although clinical trials support osimertinib's efficacy over standard epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in metastatic EGFR-mutant...